LOGLIO, ALESSANDRO
LOGLIO, ALESSANDRO
Universita' degli Studi di MILANO
Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro
2023 M. Rossi, A. Vecchi, C. Tiezzi, V. Barili, P. Fisicaro, A. Penna, I. Montali, S. Daffis, S. Fletcher, A. Gaggar, J. Medley, M. Graupe, L. Lad, A. Loglio, R. Soffredini, M. Borghi, T. Pollicino, C. Musolino, A. Alfieri, F. Brillo, D. Laccabue, M. Massari, C. Boarini, G. Abbati, G. Pedrazzi, G. Missale, P. Lampertico, C. Ferrari, C. Boni
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension
2022 E. Degasperi, M. Anolli, S.C. UCEDA RENTERIA, D. Sambarino, M. Borghi, R. Perbellini, C. Scholtes, F. Facchetti, A. Loglio, S. Monico, M. Fraquelli, A. Costantino, F. Ceriotti, F. Zoulim, P. Lampertico
Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis
2022 A. Loglio, P. Ferenci, S.C. UCEDA RENTERIA, C. Tham, C. Scholtes, H. Holzmann, F. van Bömmel, M. Borghi, R. Perbellini, A. Rimondi, E. Farina, E. Trombetta, M. Manunta, L. Porretti, D. Prati, F. Ceriotti, F. Zoulim, A. Bertoletti, P. Lampertico
Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients
2021 A. Papatheodoridi, A. Chatzigeorgiou, L. Chrysavgis, P. Lembessis, A. Loglio, F. Facchetti, E. Cholongitas, M. Koutsilieris, P. Lampertico, G. Papatheodoridis
Novel Therapies That May Cure Chronic Hepatitis B Virus.
2021 A. Loglio, M. Viganò, P. Lampertico
The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy
2020 A. Loglio, M. Iavarone, F. Facchetti, D. Di Paolo, R. Perbellini, G. Lunghi, F. Ceriotti, C. Galli, M.T. Sandri, M. Vigano, A. Sangiovanni, M. Colombo, P. Lampertico
How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals?
2020 A. Loglio, P. Lampertico
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B
2020 G.V. Papatheodoridis, G.N. Dalekos, R. Idilman, V. Sypsa, F. Van Boemmel, M. Buti, J.L. Calleja, J. Goulis, S. Manolakopoulos, A. Loglio, M. Papatheodoridi, N. Gatselis, R. Veelken, M. Lopez-Gomez, B.E. Hansen, S. Savvidou, A. Kourikou, J. Vlachogiannakos, K. Galanis, C. Yurdaydin, R. Esteban, H.L.A. Janssen, T. Berg, P. Lampertico
Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide
2020 L. Roade, A. Loglio, M. Borghi, M. Riveiro-Barciela, R. Soffredini, F. Facchetti, D. di Paolo, D. Tabernero, G. Lunghi, R. Esteban, M. Buti, P. Lampertico
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B
2020 G.V. Papatheodoridis, V. Sypsa, G.N. Dalekos, C. Yurdaydin, F. Van Boemmel, M. Buti, J.L. Calleja, H. Chi, J. Goulis, S. Manolakopoulos, A. Loglio, T. Voulgaris, N. Gatselis, O. Keskin, R. Veelken, M. Lopez-Gomez, B.E. Hansen, S. Savvidou, A. Kourikou, J. Vlachogiannakos, K. Galanis, R. Idilman, R. Esteban, H.L.A. Janssen, T. Berg, P. Lampertico
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir
2019 M. Vigano, A. Loglio, S. Labanca, S. Zaltron, F. Castelli, P. Andreone, V. Messina, R. Ganga, N. Coppola, A. Marrone, M. Russello, A. Marzano, A. Tucci, G. Taliani, M. Fasano, S. Fagiuoli, E. Villa, F. Bronte, T. Santantonio, G. Brancaccio, V. Occhipinti, F. Facchetti, G. Grossi, M. Rumi, P. Lampertico
Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis : a case report of 3 patients
2019 A. Loglio, P. Ferenci, S.C. Uceda Renteria, C.Y.L. Tham, F. van Bommel, M. Borghi, H. Holzmann, R. Perbellini, E. Trombetta, S. Giovanelli, L. Greco, L. Porretti, D. Prati, F. Ceriotti, G. Lunghi, A. Bertoletti, P. Lampertico
Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy
2019 A. Loglio, M. Iavarone, M. Vigano, A. Orenti, F. Facchetti, I. Cortinovis, G. Lunghi, F. Ceriotti, V. Occhipinti, M. Rumi, A. Sangiovanni, M. Colombo, P. Lampertico
Hepatitis D–how is the fight against this foe going?
2019 A. Loglio, S. Segato, P. Lampertico
Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients
2019 B. Testoni, F. Lebossé, C. Scholtes, F. Berby, C. Miaglia, M. Subic, A. Loglio, F. Facchetti, P. Lampertico, M. Levrero, F. Zoulim
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma
2018 A. Loglio, M. Viganò, G. Grossi, S. Labanca, M. Goldaniga, A. Pompa, L. Farina, M. Rumi, P. Corradini, F. Facchetti, G. Lunghi, L. Baldini, P. Lampertico
Treatment of hepatitis B : is there still a role for interferon?
2018 M. Viganò, G. Grossi, A. Loglio, P. Lampertico
IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients
2018 E. Galmozzi, F. Facchetti, G. Glenda, A. Loglio, M. Vigano', L. Giovanna, M.G. Colombo, P. Lampertico
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population
2018 G.V. Papatheodoridis, V. Sypsa, G. Dalekos, C. Yurdaydin, F. van Boemmel, M. Buti, J. Goulis, J.L. Calleja, H. Chi, S. Manolakopoulos, A. Loglio, S. Siakavellas, N. Gatselis, O. Keskın, M. Lehretz, S. Savvidou, J. de la Revilla, B.E. Hansen, A. Kourikou, I. Vlachogiannakos, K. Galanis, R. Idilman, M. Colombo, R. Esteban, H.L.A. Janssen, T. Berg, P. Lampertico
Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance
2018 G. Glenda, A. Loglio, F. Facchetti, B. Marta, R.M. Soffredini, E. Galmozzi, L. Giovanna, G. Anuj, P. Lampertico